Navigation Links
IMF Launches World’s First DNA Database for Myeloma Patients

close.

"They chose the larger one over and over," Langerhans said. "All females had the same preference." A tenet of Langerhans's study was his belief that the gonopodium could be viewed as a secondary sexual trait ?similar to a peacock's tail, meant to enhance reproductive opportunity and selected by the female ?rather than a primary sexual trait ?which is the actual reproductive organ itself, simply meant to transfer sperm. Historically, genitalia were not believed to be subject to such sexual selection.

"Male genitalia can be seen as just another morphological character, and if you think of them that way, females might be choosing just as they would for any morphological trait," he said. "This at least partially explains the variability in male genital morphology."

Using this study as a springboard, Langerhans is exploring the role of genital divergence in the process of speciation. Divergence in a copulatory organ might be especially important in speciation -- owing to its obvious link to reproduction, which largely defines species boundaries. Evolutionary changes in male genital morphology between populations may result in reproductive incompatibility when populations merge again in the future, resulting in the generation of new species.

"Since gonopodium size is highly variable among livebearing fish species -- ranging from less than 20 percent of the body length to more than 70% -- I am extending the results reported in the PNAS paper -- divergence of genital size within species -- to an investigation of diversification in genital size between species, inferring possible modes of speciation. Since variation in predator regime exists between as well as within species, we can test specific theoretical predictions regarding genital evolution to evaluate what processes might have caused the patterns."

Langerhans also plans to examine whether other species of livebearing fish also exhibit female mating preference for males w
'"/>

Source:


Page: 1 2 3 4

Related biology news :

1. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
2. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
3. Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005
4. Biologist Discovers What May Be World’s ‘Pickiest?Mates
5. Timing is everything: First step in protein building revealed
6. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
7. First atlas of key brain genes could speed research on cancer, neurological diseases
8. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
9. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
10. First real-time view of developing neurons reveals surprises, say Stanford researchers
11. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
Post Your Comments:
Breaking Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4